ACHV:NSD-Achieve Life Sciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.77

Change

-0.10 (-3.48)%

Market Cap

USD 0.05B

Volume

0.03M

Avg Analyst Target

USD 14.00 (+405.42%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ACHV Stock Forecast & Price:
Based on the Achieve Life Sciences Inc stock forecasts from 2 analysts, the average analyst target price for Achieve Life Sciences Inc is USD 14.00 over the next 12 months. Achieve Life Sciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Achieve Life Sciences Inc is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Achieve Life Sciences Inc’s stock price was USD 2.77. Achieve Life Sciences Inc’s stock price has changed by -3.82% over the past week, +23.11% over the past month and -61.69% over the last year.

About Achieve Life Sciences Inc (ACHV:NSD)

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that inte ...Read More

Company Website : https://www.achievelifesciences.com

Address : 1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

Employees : 16

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.13

52 Week High : 8.61

Short Ratio : 5.07

52 Week Low : 2.00

Shorted Shares : 334,046

200 Day Moving Average : 5.39

Shorted Shares Previous Month : 299,228

50 Day Moving Average : 2.83

Shares Held By Insiders : 0.37%

Short Percentage : 3.45%

Shares Held by Institutions : 27.60%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.03 (+0.33%)

 USD80.34B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

-5.40 (-0.73%)

 USD80.18B 15.51 11.82
MRNA Moderna Inc

-2.23 (-1.27%)

 USD67.38B 6.33 4.43
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.12 (+1.31%)

 USD37.58B 3.75 1.66
GMAB Genmab AS

-0.52 (-1.16%)

 USD29.87B 37.36 3.53
ALNY Alnylam Pharmaceuticals Inc

-4.41 (-2.11%)

 USD26.17B N/A -26.97
SGEN Seagen Inc

-3.85 (-3.18%)

 USD22.92B 55.02 -38.67
ARGX argenx NV ADR

-1.28 (-0.34%)

 USD21.49B N/A -20.63
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ACHV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.40% 40% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.40% 40% F 25% F
Trailing 12 Months  
Capital Gain -61.53% 49% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.53% 49% F 28% F
Trailing 5 Years  
Capital Gain -89.59% 28% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.59% 27% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -21.05% 33% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.05% 33% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 61.82% 32% F 20% F
Risk Adjusted Return -34.05% 47% F 31% F
Market Capitalization 0.05B 34% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.80 62% D- 89% B+
Price/Book Ratio 49.89 3% F 2% F
Price / Cash Flow Ratio -1.74 42% F 54% F
EV/EBITDA -1.35 57% F 62% D-
Management Effectiveness  
Return on Equity -214.13% 13% F 8% F
Return on Invested Capital -82.48% 27% F 16% F
Return on Assets -75.28% 8% F 4% F
Debt to Equity Ratio 53.21% 30% F 36% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.07 44% F 28% F
Short Percent 3.45% 50% F 39% F
Beta 1.13 49% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.